D.E. Shaw & Co
CRSP icon

D.E. Shaw & Co’s CRISPR Therapeutics CRSP Stock Holding History

D.E. Shaw & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.9M Sell
108,200
-34,500
-24% -$1.82M ﹤0.01% 2266
2026
Q1 		$6.79M Sell
142,700
-238,400
-63% -$12.6M ﹤0.01% 1951
2025
Q4 		$20M Buy
381,100
+20,800
+6% +$1.25M 0.01% 1243
2025
Q3 		$23.4M Buy
360,300
+226,700
+170% +$13M 0.01% 1077
2025
Q2 		$6.5M Buy
133,600
+82,200
+160% +$3.18M ﹤0.01% 1825
2025
Q1 		$1.75M Sell
51,400
-23,500
-31% -$996K ﹤0.01% 2708
2024
Q4 		$2.95M Buy
74,900
+15,600
+26% +$737K ﹤0.01% 2411
2024
Q3 		$2.79M Sell
59,300
-7,300
-11% -$370K ﹤0.01% 2438
2024
Q2 		$3.6M Sell
66,600
-151,900
-70% -$8.79M ﹤0.01% 2112
2024
Q1 		$14.9M Buy
218,500
+57,600
+36% +$4.12M 0.01% 1110
2023
Q4 		$10.1M Buy
160,900
+68,400
+74% +$3.78M 0.01% 1361
2023
Q3 		$4.2M Hold
92,500
– – ﹤0.01% 1956
2023
Q2 		$5.19M Sell
92,500
-18,000
-16% -$1.02M 0.01% 1836
2023
Q1 		$5M Sell
110,500
-37,900
-26% -$1.84M 0.01% 1938
2022
Q4 		$6.03M Buy
148,400
+32,500
+28% +$1.72M 0.01% 1912
2022
Q3 		$7.57M Hold
115,900
– – 0.01% 1618
2022
Q2 		$7.04M Buy
115,900
+48,000
+71% +$2.82M 0.01% 1748
2022
Q1 		$4.26M Sell
67,900
-2,000
-3% -$126K ﹤0.01% 2506
2021
Q4 		$5.3M Buy
69,900
+19,900
+40% +$1.74M ﹤0.01% 2307
2021
Q3 		$5.6M Buy
50,000
+10,000
+25% +$1.26M 0.01% 2003
2021
Q2 		$6.48M Buy
40,000
+30,000
+300% +$3.65M 0.01% 1838
2021
Q1 		$1.22M Sell
10,000
-10,000
-50% -$1.51M ﹤0.01% 2965
2020
Q4 		$3.06M Buy
20,000
+10,000
+100% +$1.18M ﹤0.01% 2254
2020
Q3 		$836K Hold
10,000
– – ﹤0.01% 2963
2020
Q2 		$735K Hold
10,000
– – ﹤0.01% 3132
2020
Q1 		$424K Hold
10,000
– – ﹤0.01% 3288
2019
Q4 		$609K Buy
+10,000
New +$546K ﹤0.01% 3289

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co's CRSP Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 893,812 shares worth $48.7M. The stake represents 0.02% of the portfolio and ranks #774 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in CRSP as recently as Q3 2024.

D.E. Shaw & Co first reported a position in CRSP in Q1 2018 and has held it in 24 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • D.E. Shaw & Co held 893,812 shares of CRISPR Therapeutics worth $48.7M as of Q2 2026.
  • CRISPR Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
  • CRISPR Therapeutics made up 0.02% of D.E. Shaw & Co's portfolio in Q2 2026, its #774 holding.
  • D.E. Shaw & Co first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.